Latest Small Cap Feast
Small Cap Feast
Small Cap Feast – 28 May 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
The pantry is empty, again!
TMT Investments* $3.06 $89.3m (TMT.L)
Portfolio Update— portfolio company Bolt (formerly known as Taxify), a leading international ride-hailing and transportation company ( www.bolt.eu ), announced, on 26 May 2020, that it had successfully raised EUR100 million (US$110 million) in the form of a convertible note from Naya Capital Management. The convertible note features a conversion cap of EUR1.7 billion (c.US$1.87 billion), which TMT notes is significantly higher than Bolt’s equity valuation following completion of its last funding round in June 2019. TMT also notes that the conversion cap does not imply a new firm equity valuation level and hence TMT has not adjusted the fair value of TMT’s interest in Bolt.
TMT’s five core holdings (Bolt, Backblaze, Depositphotos, Pipedrive and Scentbird) have performed well during the COVID-19 pandemic to date. These are well-established, more mature businesses, with globally diversified revenues, strong cash reserves and tens of thousands of customers, and account for approximately 75% of the Company’s NAV. A number of companies in our portfolio have experienced very strong growth as a result of significant increases in home working and larger numbers of citizens staying at home globally, and have attracted investment at higher conversion caps via convertible notes in recent weeks. At the same time, a small number of companies that are more exposed to physical interaction, are naturally experiencing some challenges and are adapting their business models as a result.
Synairgen 47.5p £71m (SNG.L)
Recruitment of 100 hospitalised patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed. Richard Marsden, CEO of Synairgen, commented: “We are pleased to have now completed recruitment in this important study, with initial trial data expected in July 2020. A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic.”
Columbus Energy 1.95p £17.9m (CERP.L)
Submission to the Ministry of Energy and Energy Industries (Trinidad & Tobago) a drilling application for the Saffron 2 well in the South West Peninsula.
- Saffron 2 to be drilled as a twin to Saffron 1, from the same drill pad
- Saffron 2 to target the Lower Cruse intervals encountered in drilling Saffron 1, with a targeted Total Depth of 4557 feet
- The key objective of Saffron 2 is an extended production test and subsequent conversion to a production well aimed to produce the circa 40° API oil encountered in Saffron 1
- Drilling Application consistent with commercial arrangement for a full carry of Saffron 2, as announced 27 April 2020
- Approval of the Drilling Application by the Ministry would allow drilling in Q3 2020
Oncimmune Holdings 103.5p £65.7m (ONC.L)
Oncimmune has signed a further contract with Roche to profile autoantibodies in patient samples collected during cancer immunotherapy trials.
Following closely on the completion of a successful foothill project with Roche, which was undertaken over the last two months, this new contract provides Oncimmune with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling.
Sopheon 763p £76.4m (SPE.L)
New Sopheon Release Integrating Microsoft Teams .Work-from-home has accentuated need for information transparency, connected decision making and ad hoc collaboration. The international provider of software, expertise, and best practices for Enterprise Innovation Performance, today releases Accolade® version 13.1 and Accolade Connect for Microsoft® 365 turning simple meetings into true workstream collaboration events and advancing context-aware communication.
Innovation and product development are highly cross-functional and collaboration-intensive activities. Now, for the first time, innovation teams in any industry can capitalize on their investment in Microsoft 365 (online and desktop) and Microsoft Teams in particular, to collaborate on Accolade-managed initiatives ranging from digital transformation to new product development and operational excellence.
E-therapeutics 22.75p £73.4m (ETX.L)
ETX today announces its expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes and the creation of a Scientific Advisory Board headed by Dr Paul Burke.
e-therapeutics has a unique computational approach to drug discovery. Its Network-driven Drug Discovery (NDD) platform leverages its machine learning-enhanced database of over 15 million small molecule compounds to perform functional in silico phenotypic screens. In addition, its Genome-Associated Interactions Network (GAINs) proprietary platform enables the Company to distil actionable outcomes from complex genomic datasets. GAINs outputs are well suited to genetic medicine approaches as therapeutic interventions. As such, RNAi is an area that the Company plans to explore to harness computational drug discovery outcomes, both internally and in partnership with collaborators.
Blue Star Capital 0.11p £3.84m (BLU.L)
Update regarding its investee company SatoshiPay.
On 28 May 2020, the Stellar Development Foundation (“SDF”) announced that it had made a strategic investment of $550,000 by way of convertible loan notes. This investment marks the third investment made by SDF through its Enterprise Fund and will support SatoshiPay to continue to develop its B2B solution for commercial, cross-border payments and its digital wallets. SatoshiPay was one of the first businesses to use Stellar commercially and has, to date, processed €650,000 in payments from over 200,000 accounts. SatoshiPay’s open-source wallet for the Stellar network, Solar, has been downloaded more than 25,000 times in 40 countries. The funds will be used to primarily help develop and market the SatoshiPay B2B solution. The company is currently testing this product and expects to have a product in closed alpha testing within 8 weeks.
Thor Mining*0.325p £3.5m (THR.L)
Trading in the shares of the Company have been halted on the Australian Securities Exchange effective from Thursday 28 May 2020 in accordance with ASX Listing Rule 17.1, pending an announcement related to the entering into an exclusivity arrangement in respect of a potential acquisition by the Company and an associated fundraising.
The ASX trading halt will remain in place until the earlier of the commencement of trading on Wednesday 3 June 2020 or the release of an announcement by the Company.
Trading in the Company’s ordinary shares will continue on AIM during this period.
Attis Oil & Gas 0.016p £0.6m (AOGL.L)
Memorandum of Understanding (MOU) with a North American focussed oil and gas company (in relation to the potential acquisition of that company has been terminated, due to a number of factors, not least the impact of the Global Coronavirus pandemic on oil prices, and the current economic conditions . Trading on AIM has recommenced. Placing of £500k at at 0.0115 pence plus a £100k broker option. Holders of £370,543.14 (principal plus accrued interest) of a Bridge Loan have elected to convert at 0.0075 pence per share
Salt Lake Potash 29.25p £102.5m (SO4.L)
Results of chemical analysis on a bulk sample from its Kainite harvest ponds at the Lake Way Project, showing above the modelled average Potassium grades.
A bulk sample of Harvest Salt from the Stage 1 Kainite Ponds was collected in March to confirm plant feed grades and produce mass samples of premium quality SOP for end user customers.
Chemical analysis of these Harvest Salts has indicated potassium salts kainite and schoenite (as modelled) are present with a potassium concentration of 7.5%, above the modelled assumed plant feed of 6.8%. Sulphate concentration of 20.9% also matched expectations.
Results for other compounds, namely Sodium and Magnesium align with the anticipated plant feed grade.
The bulk sample confirms the Lake Way operation is precipitating plant feed Harvest Salts suitable for conversion to premium quality SOP in the designed flowsheet. This will be further confirmed via process testwork at Saskatchewan Research Council (SRC) in Saskatoon, Canada.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.